Wuxi AppTec Co (STU:WX8) Total Liabilities : €2,773 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Wuxi AppTec Co Total Liabilities?

Wuxi AppTec Co's Total Liabilities for the quarter that ended in Mar. 2025 was €2,773 Mil.

Wuxi AppTec Co's quarterly Total Liabilities increased from Sep. 2024 (€2,375.38 Mil) to Dec. 2024 (€2,786.05 Mil) but then declined from Dec. 2024 (€2,786.05 Mil) to Mar. 2025 (€2,773.14 Mil).

Wuxi AppTec Co's annual Total Liabilities declined from Dec. 2022 (€2,405.28 Mil) to Dec. 2023 (€2,331.21 Mil) but then increased from Dec. 2023 (€2,331.21 Mil) to Dec. 2024 (€2,786.05 Mil).

Wuxi AppTec Co Total Liabilities Historical Data

The historical data trend for Wuxi AppTec Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co Total Liabilities Chart

Wuxi AppTec Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

1,706.11

2,274.57

2,405.28

2,331.21

2,786.05

Wuxi AppTec Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															2,413.42	2,471.79	2,375.38	2,786.05	2,773.14

Wuxi AppTec Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Wuxi AppTec Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2128.359	+	(459.887	+	197.805
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2,786

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	10536.234	-	7750.184
	=	2,786

Wuxi AppTec Co's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2408.27	+	(177.248	+	187.622
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	2,773

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	10783.618	-	8010.478
	=	2,773

Wuxi AppTec Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Wuxi AppTec Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (STU:WX8) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

WUXIF:USA WUXAY:USA 02359:Hong Kong WX8:Germany 603259:China

Address

288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai, CHN, 200131

Website

https://www.wuxiapptec.com

Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by China, Europe, and other regions.

Wuxi AppTec Co Headlines

No Headlines